xB3-I2S

xB3-I2S is an experimental fusion biologic that links Bioasis’ proprietary xB3 blood–brain barrier (BBB) shuttle peptide to iduronate-2-sulfatase (I2S), the lysosomal enzyme deficient in Hunter syndrome (mucopolysaccharidosis type II, MPS II). Preclinical studies in an MPS II knockout mouse model have shown that the xB3-I2S fusion increases I2S uptake into the brain and is associated with cellular and biochemical changes consistent with restored enzyme activity, supporting its potential to address the currently untreatable central nervous system manifestations of Hunter syndrome.[1][4][10] The construct is being developed by Bioasis Technologies as a BBB-penetrant enzyme replacement therapy candidate leveraging the xB3 platform to deliver large biologics into the CNS for lysosomal storage and other neurodegenerative disorders.[1][4][10][13]

Other names

xB3 peptide-I2S fusion moleculexB-3 peptide-I2S fusion moleculexB 3 peptide-I2S fusion molecule